SAN DIEGO--(BUSINESS WIRE)--Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes company with unique, patent-protected product candidates that combine approved prescription drugs with the pure trace minerals chromium and vanadium, today announced it has selected Charles River Laboratories to perform a 28-day renal-focused safety and toxicology study for its lead product candidate, AKP-020, otherwise known as bis(ethylmaltolato)oxovanadium (IV), or BEOV. Akesis licensed AKP-020, which is a novel vanadium containing compound that has shown considerable potential as a treatment for patients with Type 2 diabetes, from the University of British Columbia in March 2007.
